国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期

Purpose: To assess the impact of cell type, age, and gender in addition to pathologic tumor, node, metastasis (TNM) stage in surgically managed stage I-IIIA non-small cell lung cancer (NSCLC) cases from the international staging database of the International Association for the Study of Lung Cancer. Material and Methods: From the 67,725 cases of NSCLC submitted to the staging database, 9137 surgically managed cases were selected for which all the following variables were available: pathologic stage, age, gender, and specific histologic cell type. Performance status and smoking history were examined in subsets. Methods used were Cox proportional hazards regression and recursive partitioning and amalgamation (RPA) analyses. Results: Pathologic TNM stage, age, and gender were all independently prognostic for survival. The bronchioloalveolar carcinoma (BAC) subtype had superior survival over other cell types despite the potential for heterogeneity in this group. Adjusted comparisons revealed a small survival advantage for squamous cell carcinomas over non-BAC adenocarcinoma histology and also over large cell, though the effect appeared to be limited to the male patients. RPA revealed the importance of TNM stage primarily, and age was prognostic within stage groups. Cell type was not found to add prognostic value in the RPA analysis. Prognostic groups were formed based on the RPA output, and the prognostic value of these groupings was validated using the North American Surveillance, Epidemiology, and End Results Registries. Performance status and smoking history were prognostic in the subsets where data were available. Effects of other variable were not influenced by the inclusion of smoking status in regression models. Conclusions: Age and gender are confirmed as important prognostic factors in surgically resected NSCLC. Cell type is less important, although the small population of cases classified as BAC have a survival advantage over other histologies, and there may be a small survival advantage for squamous cell carcinomas over non-BAC adenocarcinomas. Imbalances between stage, gender, and cell type at presentation may lead to a misleading result with respect to cell type in unadjusted analyses. Pathologic TNM category is the most important prognostic factor in this analysis.

[1]  F. Detterbeck,et al.  Turning Gray: The Natural History of Lung Cancer Over Time , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  大堀 理,et al.  Memorial Sloan-Kettering Cancer Center , 2020, Definitions.

[4]  A. Giovagnoni,et al.  Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. , 2005, Lung cancer.

[5]  G. Bepler,et al.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. , 2004, Chest.

[6]  A. Marchetti,et al.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. , 2007, The Journal of clinical investigation.

[7]  J. Crowley,et al.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. E. Morgan,et al.  Do women live longer following lung resection for carcinoma? , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  Yohu Watanabe.  TNM classification for lung cancer. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[10]  Marcin Skrzypski,et al.  Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung , 2008, Clinical Cancer Research.

[11]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[12]  John Crowley,et al.  Some Exploratory Tools for Survival Analysis , 1997 .

[13]  Y. Shimosato.  [Histological Typing of Lung and Pleural Tumors (3rd edition, 1999): Malignant epithelial tumors]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[14]  J. Jett,et al.  A prognostic model for advanced stage nonsmall cell lung cancer , 2006, Cancer.

[15]  E. Wynder,et al.  The changing epidemiology of smoking and lung cancer histology. , 1995, Environmental health perspectives.

[16]  J. Crowley,et al.  The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  R. Arriagada,et al.  Impact of adjuvant chemotherapy (CT) on survival and local-control in non-small cell lung cancer (NSCLC): Results of the international adjuvant lung cancer trial (IALT) , 2004 .

[18]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[21]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[23]  S. Ou,et al.  Prognostic factors for survival of stage I nonsmall cell lung cancer patients , 2007, Cancer.

[24]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[25]  H. Dienemann,et al.  Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. , 2007, Lung cancer.

[26]  Kenji Eguchi,et al.  A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Lung cancer survival in Spain and prognostic factors: a prospective, multiregional study. , 2008, Lung cancer.

[28]  Y. Sakao,et al.  The Impact of Cigarette Smoking on Prognosis in Small Adenocarcinomas of the Lung: The Association Between Histologic Subtype and Smoking Status , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  K. Ishikawa,et al.  Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer--a multicenter study. , 2005, Lung cancer.

[30]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Y. Maehara,et al.  Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. , 2006, The Annals of thoracic surgery.

[32]  C. Foucault,et al.  Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. , 2006, The Annals of thoracic surgery.

[33]  G. Hédelin,et al.  Specific Features of Non-small Cell Lung Cancer in Women: A Retrospective Study of 1738 Cases Diagnosed in Bas-Rhin between 1982 and 1997 , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Zhifu Sun,et al.  Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  E. Brambilla,et al.  Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer , 2005, European Respiratory Journal.

[37]  J. Crowley,et al.  The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer , 2006 .

[38]  Marcin Skrzypski,et al.  A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[39]  E. Vokes,et al.  Sex-associated differences in survival of patients undergoing resection for lung cancer. , 2000, The Annals of thoracic surgery.

[40]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[41]  Hiroshi Okazaki,et al.  Never‐smoking nonsmall cell lung cancer as a separate entity , 2008, Cancer.

[42]  Gilmore Hr,et al.  Armed Forces Institute of Pathology. , 1968, Oral surgery, oral medicine, and oral pathology.

[43]  E. Paci,et al.  Gender differences in non-small cell lung cancer: a population-based study. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[44]  B. Milleron,et al.  La recherche clinique en cancérologie thoracique: place et rôle de l’Intergroupe francophone de cancérologie thoracique (IFCT) , 2009, Oncologie.

[45]  B. Møller,et al.  Survival after resection for primary lung cancer: a population based study of 3211 resected patients , 2006, Thorax.

[46]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[47]  M. Iannuzzi,et al.  Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. , 2005, Lung cancer.

[48]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  L. Einhorn.  First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.